Trial Profile
A trial assessing Coronavirus vaccine
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 18 Jan 2021
Price :
$35
*
At a glance
- Drugs Coronavirus vaccine (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 11 Jan 2021 According to a Geovax media release, National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a Small Business Innovative Research (SBIR) grant in support of its development of a vaccine against SARS-CoV-2, the virus that causes COVID-19
- 20 Mar 2020 New trial record
- 18 Mar 2020 According to a Geovax media release, this trial is expected to start before the end of this year.